Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech will retain responsibility for development, global clinical activities and manufacturing and will supply finished product to commercial partners under exclusive supply arrangements. The company is actively securing partnerships with major distributors like Sandoz to expand market access while managing capital efficiently.
Cyborg Score Rationale
Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab). Recent leadership transition and significant patent resolution with Regeneron demonstrate execution capability, though capital intensity and biosimilar market competition remain risks.
Top Insights
Alvotech secured a USD 100 million senior term loan facility maturing in December 2027 to bolster liquidity and support R&D and global product launches through 2026
Alvotech entered into supply and commercialization agreements with Sandoz covering one ophthalmology candidate in Canada and three immunology/gastroenterology candidates in Australia and New Zealand
Alvotech reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech's biosimilar to Eylea 2mg
Founder Róbert Wessman stepped down as CEO at end of Q1 2026 and continues as Executive Chairman; Lisa Graver appointed Chief Executive Officer
Named Competitors
Biosimilar Portfolio — Leading commercial partner for Alvotech's biosimilars in multiple regions
Biosimilar Division — Major competitor in biosimilar development and commercialization
Biosimilar Development — South Korean pure-play biosimilar developer